Send to

Choose Destination
PLoS One. 2012;7(8):e43075. doi: 10.1371/journal.pone.0043075. Epub 2012 Aug 17.

C-reactive protein, interleukin 6 and lung cancer risk: a meta-analysis.

Author information

School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.



Epidemiologic findings are inconsistent concerning the associations between C-reactive protein (CRP), interleukin 6 (IL-6) and lung cancer risk. We conducted a meta-analysis of epidemiologic studies to examine these associations.


A systematic literature search up to October 2011 was performed in MEDLINE and EMBASE. Study-specific risk estimates were pooled using a random-effects model.


The 10 studies on CRP involved a total of 1918 lung cancer cases. The pooled RR of lung cancer for one unit change in natural logarithm (ln) CRP was 1.28 (95% CI 1.17-1.41). There was no statistically significant heterogeneity among studies (P = 0.116; I(2) = 36.6%). We also found that CRP was significantly associated with increased risk of lung cancer among men (RR 1.18, 95% CI 1.09-1.28) but not among women. The 5 studies on IL-6 involved a total of 924 lung cancer cases. The pooled RR of lung cancer for one unit change in ln IL-6 was 1.28 (95% CI 0.92-1.79), however, statistically significant heterogeneity was found. After excluding the study contributing most to the heterogeneity, the summary estimate was essentially unchanged.


CRP was associated with increased risk of lung cancer, especially among men. There was no significant association between IL-6 and lung cancer risk.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center